Merck and Ridgeback Biotherapeutics Covid-19 pill less effective
Merck has shared these additional analyses with the FDA and they will be presented to the FDA’s Antimicrobial Drugs Advisory Committee on Nov. 30th
Merck has shared these additional analyses with the FDA and they will be presented to the FDA’s Antimicrobial Drugs Advisory Committee on Nov. 30th
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
Arrowhead to receive US $ 120 million upfront payment for Phase 1/2 program for NASH and is eligible to receive potential milestone payments and royalties on commercial sales
Gavreto is the first and only precision medicine approved in the EU for first-line treatment of people with RET fusion-positive advanced NSCLC
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
The nutraceutical sector is on the cusp of exponential growth and Covid-19 has accelerated the pace of its applications. Dr R.B Smarta, CMD, Interlink, shares his perspective on the growth opportunities and challenges for the sector
The vaccine will be manufactured and marketed in the Philippines by SII under the brand name Covovax
Nelarabine is in a class of medications called antimetabolites
If approved or authorized, Paxlovid would be the first oral antiviral of its kind, to combat SARS-CoV-2
Subscribe To Our Newsletter & Stay Updated